View Older Stories View More Recent Stories

May 13, 2025 06:45AM Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
May 8, 2025 06:45AM Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
May 7, 2025 06:45AM Merck to Participate in the Bank of America 2025 Global Healthcare Conference
Apr 29, 2025 06:57AM Merck (MRK) Breaks Ground on New $1B Biologics Center of Excellence in Wilmington, Delaware
Apr 29, 2025 06:45AM Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
Apr 27, 2025 12:00PM KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally
Apr 24, 2025 08:34AM Halozyme Therapeutics (HALO) Sues Merck (MRK) for Patent Infringement over Subcutaneous Keytruda Formulation
Apr 24, 2025 08:00AM Curiosity Cube 2025: MilliporeSigma’s Mobile Science Labs Tour Globally to Bring STEM Education to Students
Apr 24, 2025 06:30AM Merck Announces First-Quarter 2025 Financial Results
Apr 11, 2025 12:21PM MRK IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important April 14 Deadline in Securities Class Ac
Apr 10, 2025 12:14PM MRK FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
Apr 8, 2025 02:40PM MRK DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
Apr 6, 2025 12:26PM MRK FINAL DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Clas
Apr 4, 2025 01:17PM MRK FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Actio
Apr 3, 2025 01:11PM MRK FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - M
Apr 1, 2025 06:06PM ROSEN, NATIONAL TRIAL LAWYERS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Apr 1, 2025 06:45AM Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
Mar 31, 2025 01:58PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 31, 2025 10:00AM Merck (MRK) Report WINREVAIR Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76%
Mar 31, 2025 10:00AM WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the
Mar 29, 2025 09:19AM ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 27, 2025 11:01AM Merck (MRK) Reports Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous KEYTRUDA
Mar 27, 2025 11:01AM Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77
Mar 26, 2025 06:45AM Merck (MRK) Receives EU Approval for CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Mar 26, 2025 06:45AM European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Mar 25, 2025 03:35PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 25, 2025 06:45AM Merck (MRK) Enters Exclusive License Agreement for HRS-5346
Mar 25, 2025 06:45AM Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Mar 24, 2025 03:30PM ROSEN, A TOP RANKED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 23, 2025 12:18PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 22, 2025 11:24AM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 21, 2025 11:18AM ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 19, 2025 06:52PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 19, 2025 06:45AM Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
Mar 18, 2025 06:47PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 17, 2025 06:41PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 16, 2025 05:22PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 15, 2025 05:22PM ROSEN, A TOP RANKED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 14, 2025 05:17PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 12, 2025 11:26AM Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
Mar 11, 2025 10:05PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 11, 2025 06:45AM Merck (MRK) Unveils New Facility to Increase Vaccine Production Capacity
Mar 11, 2025 06:45AM Merck Unveils New Facility to Increase Vaccine Production Capacity
Mar 9, 2025 01:21PM ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 7, 2025 11:05PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 6, 2025 07:57PM ROSEN, A TOP RANKED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 5, 2025 07:52PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 4, 2025 07:46PM TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 3, 2025 07:18PM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 2, 2025 07:02PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
View More Recent Stories View Older Stories